MSD takes on Pfizer's Prevnar with new Capvaxive approval
MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.
Newsletters and Deep Dive digital magazine
MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.
The first generic of Roche's drug for influenza, Xofluza, has been approved by the FDA and should be available in time for this year's flu season.
Sanofi's on-body injector version of multiple myeloma therapy Sarclisa has been cleared in the UK, which will be the first market for the product.
GSK has helped top up the antibiotic armamentarium in the US, after securing the first FDA approval for an oral carbapenem, Utebzi.
Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.
Editor's Picks
Newsletters and Deep Dive
digital magazine